Last checked at 30 Jun 2015 07:00
30 June 2015
Deltex Medical Group plc
("Deltex Medical", "the Company" or "the Group")
New US platform programme account opened
Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), announces that it has opened a new account to its platform programme in the USA.
The account is a major hospital in North-West USA. It is part of the 26 hospital system covered by the procurement framework agreement, as announced on 15 January 2015, and is the third platform programme account within this system.
In accordance with the framework agreement, the hospital is committed to purchase at least 30 probes per month with an expectation of increasing volumes in the future. The Company is deploying an existing local dedicated trainer to support the new account.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"This is the fifth account added to our US platform programme this year and the eleventh in total. We are encouraged that, with a procurement framework in place, we were able to progress from initial demonstration through clinical evaluation and into an implementation programme in under three months. We are targeting further hospitals in this system in our drive to get to 30 platform programme accounts by mid-2016."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman |
|
Ewan Phillips, Chief Executive |
|
Barry Curtis, Company Secretary |
|
|
|
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson | 020 7533 7727
|
Financial Public Relations | |
Newgate | 020 7653 9850 |
Tim Thompson | |
Robyn McConnachie Ed Treadwell |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.